The burden of non-Hodgkin lymphoma in Central and South America  by Diumenjo, Maria C. et al.
Cancer Epidemiology 44S (2016) S168–S177The burden of non-Hodgkin lymphoma in Central and South America$
Maria C. Diumenjoa, Graciela Abriatab, David Formanc, Monica S. Sierrac,*
aRegistro Provincial de Tumores de Mendoza, Argentina
bNational Cancer Institute, Argentina
c International Agency for Research on Cancer, Section of Cancer Surveillance, France
A R T I C L E I N F O
Article history:
Received 27 November 2015
Received in revised form 7 May 2016
Accepted 23 May 2016
Keywords:
Non-Hodgkin lymphoma
Lymphomas
Latin America
A B S T R A C T
Rationale and objective: The burden of non-Hodgkin lymphoma (NHL) has increased in some Central and
South American countries. We describe the current patterns and trends in NHL incidence and mortality in
Central and South America.
Methods: We obtained regional- and national-level incidence data from 48 population-based cancer
registries in 13 countries, and national-level cancer mortality data from the WHO mortality database for
18 countries. We estimated world population age-standardized incidence rates (ASRs) and mortality rates
(ASMRs) per 100,000 person-years for 2003–2007, and presented distributions by histological subtype.
Results: NHL incidence and mortality rates varied between countries by 2–8- and 6-fold, respectively. ASRs
per 100,000 ranged from 1.4 to 10.9 among males and 1.3–9.2 among females. Corresponding ASMRs were
between 0.5 and 4.8 among males and between 0.5 and 3.0 among females. The highest incidence was
observed in Uruguay (males), Ecuador, Peru and Colombia (males). The highest mortality was seen in
Uruguayand Costa Rica. Trends in NHL incidence and mortality in Argentina, Brazil,Chile and Costa Rica did
not show marked changes. B-cell neoplasms and NHL not otherwise speciﬁed (NOS) accounted for 44% and
34% of all NHL cases. Diffuse large B-cell lymphoma, NOS, was the most frequent histological subtype.
Conclusion: The geographic variations in NHL rates may partially reﬂect differences in registration
practices, disease classiﬁcation, diagnostic practice, and death certiﬁcation quality. There is a need for
high-quality data and improvements in the accuracy of NHL histological diagnosis. Given the expected
increase in NHL, careful monitoring of rates remains a priority to guide cancer control programs.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Non-Hodgkin lymphoma (NHL) represents a heterogeneous
group of lymphoproliferative malignancies with different morphol-
ogy, immunological phenotype, genetics, molecular biology and
clinical features [1,2]. NHL is the tenth most frequent cancer
diagnosis and the 11th leading cause of cancer death in the world,
with estimates of nearly 400,000 new cases and 200,000 deaths$ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
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creativecommons.org/licenses/by-nc-nd/3.0/igo/).having occurred in 2012 [3]. NHL incidence and mortality rates vary
considerably across the globe, and rates are higher in males than
females [4–7]. The highest NHL incidence rates are seen in North
America, Europe, Oceania, and some African countries [6], whereas
the highest mortality rates are observed in New Zealand, Israel and
Canada [8]. These geographical variations may be related to
differences in demographic, environmental and other factors [6].
Rapid increases in NHL incidence and mortality rates have been
reported in the United States and some European countries over
the last few decades, but more recently rates have stabilized or
declined [1,6,9–11]. Although the reasons for the observed patterns
are not completely understood, improvements in disease diagnosis
and changes in disease classiﬁcation may partially explain the
increases in incidence, while improvements in treatment for some
NHL types may explain, at least in part, the declines in mortality.
Changes in exposure to risk factors, including some infectious
agents and immunosuppressive drugs, may also be responsible for
some of the observed patterns [1,4,6,7,12,13].
Central and South America carry approximately 7% of the global
burden of NHL, with an estimated 27,000 new cases and. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
M.C. Diumenjo et al. / Cancer Epidemiology 44S (2016) S168–S177 S16914,000 cancer deaths, making NHL the ninth most common
diagnosis and the 11th most common cause of cancer death in 2012
[3]. Increases in NHL incidence have been reported in Brazil and
Colombia from the 1970s and 1980s [14], and increases in mortality
have been reported in Colombia and Mexico since the late 1990s
[15,16]. Recent GLOBOCAN estimates have indicated that, by the
year 2030, the burden of this disease will increase in the region by
more than 60% (to 43,000 new cases and 24,000 deaths), mainly
because of aging and growth of the population [3]. Given the scant
information available on the burden in Central and South America,
we describe in this paper the incidence and mortality patterns and
trends in NHL in Central and South America (including previously
unpublished incidence data), and discuss our results in light of
factors associated with an increased risk of NHL.
2. Methods
The present analysis includes all cases registered as non-Hodgkin
lymphoma (C82–C85 and C96), as coded by the 10th edition of the
International Classiﬁcation of Diseases for Oncology (ICD-10). The
data sources and methods are described in detail in an earlier article
in this issue. In brief, we obtained regional- and national-level
incidence data from 48 population-based cancer registries in
13 countries, and national-level cancer death information from
the World Health Organization (WHO) mortality database for
18 countries. We estimated age-standardized incidence (ASR) and
mortality (ASMR) rates per 100,000 person-years using the direct
method and the World standard population [17,18]. We estimated
national ASRs by aggregating the data from the available cancer
registries using a weighted average of local rates. Registries that
provided formal consent to use data by individual year of diagnosis
for 10 years were included in the time-trend analysis (Table 1). To
describe incidence and mortality time trends, we calculated the
estimated annual percentage change (EAPC) for the most recent 10-
year period using the method proposed by Esteve et al. [19]. All of the
EAPCs were tested for equality to zero by using the corresponding
standard errors. We considered EAPCs statistically signiﬁcant if the
P-value  0.05. We conducted the data analysis in Stata version 12.1
(StataCorp) [20].
We also present the distribution of NHL by histopathological
categories. NHL tumorswere classiﬁedaccordingtothe revisedWHO
classiﬁcation system [21] and used in Cancer Incidence in Five
Continents [22]. To avoid potential misclassiﬁcation of NHL
subtypes, all codes were checked with the IARCcrgTools conversion
program provided by IARC (ICD-O-3 to ICD-10) [23]. For comparative
purposes, reﬁned histological classiﬁcations are also presented [24].
3. Results
In the most recent 5-year period about 19,000 cases and
52,000 deaths from NHL occurred in Central and South America,
accounting for 3% of the total cancer burden in both sexes; it is
among the 14 most frequently diagnosed cancers, and between the
6th and 14th most common cause of cancer-related death (Table 1).
Approximately 64% (range 55–79%) of the NHL cases were
diagnosed in men and women aged 50 years; 33% (range 20–
39%) of the cases were diagnosed under the age of 50 years, and inTable 1
Countries included in the analysis of time trends.
Country Names of registries included 
Argentina Bahia Blanca 
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 
Chile Valdivia 
Costa Rica National registry 3% (range 0–9%) of the cases the age at diagnosis was unknown
(Fig. A1).
3.1. Age-standardized incidence and mortality rates
Overall, males had higher incidence and mortality rates than
females (male-to-female ratios ranging from 1.1 to 2.6:1 and from
1.1 to 1.6:1, respectively, except in El Salvador). ASRs of NHL ranged
from 1.4 to 10.9 per 100,000 among males and from 1.3 to 9.2 per
100,000 among females. The highest ASRs in both sexes were
observed in Uruguay (males), Ecuador, Peru and Colombia (males),
while the lowest were in Bolivia and El Salvador. ASMRs ranged
between 0.5 and 4.8 per 100,000 among males and between
0.5 and 3.0 per 100,000 among females. The highest mortality rates
for both males and females were seen in Uruguay and Costa Rica,
whereas the lowest were in Guatemala and El Salvador (Table 2).
3.2. Time trends
Incidence and mortality rates of NHL in the four countries
evaluated did not showed marked changes over time (Fig. 1). In the
most recent 10-year period, the largest increases in NHL incidence
rates were seen in Costa Rica (EAPC: 1.5% for males and 2.7 for
females, P > 0.05) whereas the largest decline occurred in Chilean
males (EAPC: 2.9, P > 0.05). The largest increase in mortality was
seen in Costa Rica (EAPC: 2.8 for males and 5.9 for females, P > 0.05)
while the largest decline was in Argentinean females (EAPC: 1.3,
P > 0.05) (Fig. 2).
3.3. Distribution of NHL incident cases by histological subtype
In the most recent 5-year period, 44% (range 2–78%) of all the
NHL cases diagnosed in Central and South America were B-cell
neoplasms, 34% (range 8–62%) were NHL not otherwise speciﬁed
(NOS), 14% (range 4–22%) were unspeciﬁed malignant neoplasms,
and 7% (range 0–16%) were T-cell and NK-cell neoplasms (Table 3).
The (median) age at diagnosis was 59 years (range 0–100) for B-
cell neoplasms, 55 years (range 0–100) for T-cell and NK-cell
neoplasms, 60 (range 0–100) for NHL, NOS, 14 years (range 0–92)
for other speciﬁed, and 58 years (range 0–100) for unspeciﬁed
malignant neoplasms (Table 3).
Diffuse large B-cell lymphoma (DLBCL) NOS was the most
frequently diagnosed B-cell neoplasm, accounting for 40–62% of all
the cases diagnosed in this category, except in Cuba where small-
cell B-cell and Burkitt lymphoma were more common (43% of the
cases). Follicular lymphoma was also a frequent diagnosis in the
region, accounting for 8–21% of the B-cell neoplasm cases (except
for Chile with 3%), followed by small-cell B-cell lymphoma (range
7–22%) and marginal-zone B-cell lymphoma, NOS (range 3–15%,
except for Cuba and El Salvador with 0%) (Table 4).
Among the T-cell and NK-cell neoplasms (Table 5), mature T-
cell lymphoma NOS was the most frequently diagnosis, accounting
for 15–50% of all the tumors within this category (except for Bolivia
and Cuba, with no recorded cases) followed by and cutaneous T-
cell lymphoma NOS (14–42%, except for Bolivia, Cuba, and French
Guyana, with 0 cases).Period % of the population covered
1993–2007 0.8
1997–2006 8.0
1993–2008 2.2
1985–2007 100.0
Table 2
Age-standardized incidence and mortality rates (per 100,000) from non-Hodgkin lymphoma in Central and South America.
Incidence Mortality
Country (period) Sex Cases Crude rate ASR (W) M:F MV% Rankb Deaths Crude Rate ASR (W) M:F Rankb
Central America
Belize (2003–07) M 7 1.0 1.7 1.5 11
F 6 0.8 1.2 13
Costa Rica (2003–07) M 646 6.0 6.8 1.2 100 6 367 3.4 3.8 1.4 8
F 530 5.1 5.4 100 9 277 2.6 2.7 10
Cubaa (2004–07) M 172 10.5 7.8 1.5 98 8 983 4.3 3.4 1.5 13
F 126 7.8 5.1 98 9 697 3.1 2.2 12
El Salvadora
(1999–03)
M 147 1.1 1.4 1.0 92 6 60 0.4 0.5 1.1 13
F 165 1.2 1.3 96 10 61 0.4 0.5 14
Guatemala (2003–07) M 154 0.5 0.8 1.5 12
F 119 0.4 0.5 14
Mexicoa (2006–10) M 775 4.5 5.2 1.2 100 4 5822 2.1 3.0 1.4 8
F 704 4.0 4.4 100 7 4752 1.6 2.1 11
Nicaragua (2003–07) M 151 1.1 1.6 1.5 8
F 103 0.8 1.0 11
Panama (2003–07) M 206 2.5 2.9 1.5 8
F 153 1.9 2.0 10
South America
Argentinaa (2003–07) M 997 8.1 8.1 1.4 90 8 3761 4.0 3.5 1.6 12
F 880 6.8 5.9 90 8 3167 3.2 2.2 11
Boliviaa (2011) M 42 3.2 3.4 2.6 100 3
F 19 1.4 1.3 95 12
Brazila (2003–07) M 4254 7.6 9.1 1.4 87 10 9394 2.0 2.3 1.5 11
F 4013 6.5 6.5 87 10 7471 1.6 1.6 12
Chilea (2003–07) M 100 4.3 4.3 1.0 100 14 1421 3.5 3.4 1.4 11
F 109 4.9 4.3 100 13 1282 3.1 2.4 11
Colombiaa (2003–07) M 857 9.4 10.2 1.5 97 5 2302 2.2 2.8 1.5 10
F 724 7.2 6.9 98 9 1841 1.7 1.9 12
Ecuadora (2003–07) M 422 8.9 10.6 1.2 98 3 652 1.9 2.4 1.3 7
F 441 8.6 9.2 98 6 542 1.6 1.8 11
French Guyanaa
(2003–08)
M 38 7.7 9.5 1.4 84 6
F 26 5.2 7.0 96 8
Paraguay (2003–07) M 205 1.4 1.9 1.6 9
F 134 0.9 1.2 12
Perua (2001–05) M 875 9.5 10.2 1.2 90 5 1426 2.1 2.7 1.4 6
F 828 8.6 8.8 91 6 1123 1.7 2.0 10
Suriname (2003–07) M 22 1.8 2.0 1.4 8
F 17 1.4 1.4 10
Uruguay (2005–07) M 647 13.5 10.9 1.7 98 8 314 6.5 4.8 1.6 10
F 544 10.6 6.4 98 11 275 5.3 3.0 7
Venezuela (2003–07) M 1481 2.2 2.8 1.4 8
F 1135 1.7 2.0 9
ASR (W), age-standardized (World population) rate per 100,000; M, males; F, females; M:F, male-to-female ratio (females as the referent category); MV, microscopic
veriﬁcation.
a Incidence rates were estimated using aggregated data from regional cancer registries.
b Rank across cancer types, based on highest ASR excluding: All sites but C44 and All sites.
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This analysis of over 19,000 NHL incident cases and
52,000 deaths revealed wide geographic variation in NHL
incidence and mortality rates in Central and South America
(between 2 and 8- and 6-fold, respectively). NHL occurred more
frequently in males than in females and among the elderly, a
ﬁnding consistent with that in other studies [7,25,26].
The highest incidence rates among males observed in Uruguay,
Colombia, Peru, Ecuador (10.2–10.9) and among females in
Ecuador (9.2) and Peru (8.8) were up to 40% lower than those
observed in some countries (England, France, Italy, Israel, Norway)
and in North American countries for 2003–2007 [27]. Although, on
a global scale, the incidence of NHL in the region is lower, it is an
important cause of morbidity in both males (ranking 5th to 8th)
and females (ranking 6th).
Uruguay has the one of highest NHL mortality rates in the world
[8], perhaps due to a high frequency of cases diagnosed over the
age of 50 years. It has been shown that survival decreases with
increasing age because of differences in disease biology, hostimmune response, co-morbidities and treatment complications,
among other factors [7]. In contrast, El Salvador, Guatemala and
Nicaragua were among the countries with the lowest NHL
mortality rates in the world in both males and females for
2003–2007 [8]. Despite the relatively low mortality rates on a
global scale, NHL is an important cause of cancer mortality in these
countries, ranking between the 8th and 13th cause of cancer death
in males and between the 11th and 14th cause of cancer death in
females. The geographic variations in NHL incidence and mortality
rates may reﬂect differences in case ascertainment and registra-
tion, disease diagnosis and classiﬁcation [28].
Trends in NHL incidence and mortality rates in Argentina,
Brazil, Chile and Costa Rica did not show statistically signiﬁcant
changes. The contrasting patterns seen in males from Chile and
Costa Rica could be the result of instability of rates based on small
numbers of cases rather than a true change in the underlying
frequency of NHL occurrence. Increases in NHL incidence rates
have also been reported in Sao Pablo, Brazil, from 1970 to 1985,
while in Cali, Colombia, rates increased between 1970 and 1975
then sharply declined until 1985 [14]. In Pasto, Colombia, NHL
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2003–2007 in both males and females [29]. Mortality has
increased in Colombia from 1998 to 2008 [15] and in Mexico
from 1998 to 1999 to 2005–2007 [16]. Discrepancies in incidence
and mortality trends within the region may be due to randomvariation or changes in registration practices, classiﬁcation and
diagnosis of NHL cases, and changes in the quality of death
certiﬁcation [9,12–14,28].
We were unable to estimate incidence rates by histological
subtype given that a large proportion of NHL cases diagnosed in the
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because some cancer registries lack sufﬁciently speciﬁc data for
lineage-based classiﬁcation. Despite this, we observed that B-cell
lymphoma – speciﬁcally DLBCL NOS – was the most frequent
diagnosis in the region which is consistent with previous reports
[30–33]. DLBCL NOS is not only the most common type of lymphoma
worldwide but also the most common aggressive B-cell lymphoma
[34]. Coupled with differences in healthcare access [35], this may
partially explain some of the high mortality rates seen in the region.
Follicular lymphoma was also a frequent diagnosis in the
region, similar to the frequency reported in Colombia [31] but
lower than the reported frequency in Argentina, Brazil, and Chile
[30] and Uruguay [33]. Consistent with other reports, follicular
lymphomas in the region were diagnosed less frequently than in
North America and Western Europe [4,32].
Within the T-cell lymphomas, mature T cell was the most
frequently diagnosed subtype, followed by cutaneous and ana-
plastic large-cell lymphoma, T-cell and null-cell types. Unlike other
reports from the region [30,36–38], we observed a very low
proportion of peripheral T-cell lymphoma and NK/T-cell lympho-
ma, nasal and nasal type (<1% of all NHL), probably due to the large
proportion of unspeciﬁed cases. In a classiﬁcation study of
1028 NHL cases from Argentina, Brazil, Chile, Guatemala, and
Peru (the NHL–CSA study), Laurini et al. found a higher overall
prevalence of extranodal NK/T-cell lymphoma, nasal type (ENKTL)
in Central and South America than in North America (2.9% versus
0%, P < 0.05), with the highest frequency observed in Guatemala
(7.8%), Chile (2.6%) and Peru (2.9%) [30]. Likewise, in Mexico, ENKTL
accounted for 10% of all NHL cases (40% of all T-cell lymphomas)
[37]. In contrast, in Colombia, ENKTL represented only 0.7% of all
among NHL cases [31].
4.1. Risk factors
The geographic variations in NHL rates (and NHL subtypes)
observed across the world are thought to reﬂect differences in
etiological factors or host response to those factors in the relevant
geographic areas [4], as well as racial and environmental differ-
ences [7]. However, caution must be exercised in interpreting NHL
patterns when considered as a single disease entity, because rates
are inﬂuenced by both diagnostic and etiological factors which
may differ by subtype [39]. Before discussing the potential factors
that could explain some of the observed geographic variations in
NHL rates, one must consider also that incomplete case ascertain-
ment and registrations, and differences healthcare access, could
have inﬂuenced our results.
Several infectious agents, classiﬁed as carcinogenic to humans
by the International Agency for Research on Cancer [40], that could
potentially be relevant to the Central and South American region
are shown in Table 6.
It has been estimated that 74% (13,000/18,000) of the global
number of NHL gastric cases, 63% (6800/11,000) of the Burkitt
cases, 8% (29,000/360,000) of HCV-associated NHL cases, and 100%
of the adult T-cell cases (21,000/21,000) occurring in 2008 were
attributable to infections, with approximately 31–93% of the cases
occurring in less developed regions of the world [41].
Epstein–Barr virus (EBV) infection has been strongly associated
with an increased risk of Burkitt lymphoma, ENKTL and NHL related
to immune suppression [40]. Although the prevalence of EBV in the
region is largely unknown, there is some evidence to suggest that the
proportion of EBV-associated Burkitt lymphoma in Central and
South America and the Caribbean is intermediate between endemic
regions (Sub-Saharan Africa), where 95% of the cases are EBV-
positive, and non-endemic regions (all other world regions, except
for North Africa and the Middle East) where 20% of the cases are EBV-
positive [42]. For instance, in Brazil, approximately 53% (range 29–
Table 4
Frequency distribution of B-cell neoplasms diagnosed in males and females in Central and South America.
Type Argentinaa
(2003–2007)
n (%)
Boliviaa
(2011)
n (%)
Brazila
(2003–
2007)
n (%)
Chilea
(2003–
2007)
n (%)
Colombiaa
(2003–2007)
n (%)
Costa Rica
(2003–2007)
n (%)
Cubaa
(2004–
2007)
n (%)
Ecuadora
(2003–2007)
n (%)
El Salvadora
(1999–2003)
n (%)
French Guyanaa
(2003–2007)
n (%)
Mexicoa
(2005–2010)
n (%)
Perua
(2001–
2005)
n (%)
Uruguay (2005–
2007) n (%)
Small-cell BCL 142 (17) 8 (22) 441 (15) 10 (14) 77 (8) 84 (9) 3 (43) 45 (10) 39 (21) 3 (7) 126 (18) 85 (10) 17 (6)
Small B
lymphocytic, NOS
127 (15) 8 (22) 405 (13) 9 (13) 72 (8) 70 (8) 3 (43) 43 (9) 39 (21) 3 (7) 114 (16) 77 (9) 13 (4)
Lymphoplasmacytic 15 (2) 0 (0) 36 (1) 1 (1) 5 (1) 14 (2) 0 (0) 2 (0) 0 (0) 0 (0) 12 (1) 8 (1) 4 (1)
Mantle-cell
lymphoma
23 (3) 0 (0) 54 (2) 1 (1) 22 (2) 58 (6) 0 (0) 3 (1) 1 (1) 2 (4) 16 (2) 22 (2) 19 (6)
Mixed small- and
large-cell, diffuse
40 (5) 4 (11) 91 (3) 3 (4) 18 (2) 10 (1) 0 (0) 47 (10) 25 (13) 1 (2) 34 (5) 42 (5) 7 (2)
Mediastinal large
BCL
0 (0) 0 (0) 12 (0) 0 (0) 1 (0) 2 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 1 (0) 0 (0)
DLBCL 369 (45) 17 (47) 1520 (50) 42 (59) 543 (60) 480 (53) 0 (0) 288 (62) 106 (57) 20 (44) 326 (46) 557 (62) 144 (48)
NOS 359 (43) 17 (47) 1458 (48) 38 (54) 523 (57) 461 (51) 0 (0) 286 (62) 105 (56) 18 (40) 296 (42) 549 (61) 141 (47)
Immunoblastic,
NOS
10 (1) 0 (0) 62 (2) 4 (6) 20 (2) 19 (2) 0 (0) 2 (0) 1 (1) 2 (4) 30 (4) 8 (1) 3 (1)
Burkitt lymphoma 12 (1) 1 (3) 195 (6) 1 (1) 57 (6) 55 (6) 3 (43) 4 (1) 1 (1) 4 (9) 42 (6) 8 (1) 16 (5)
Splenic marginal
zone BCL
12 (1) 0 (0) 10 (0) 0 (0) 3 (0) 3 (0) 0 (0) 0 (0) 0 (0) 2 (4) 4 (1) 1 (0) 1 (0)
Follicular lymphoma 175 (21) 3 (8) 488 (16) 2 (3) 128 (14) 154 (17) 1 (14) 60 (13) 15 (8) 9 (20) 115 (16) 135 (15) 84 (28)
Unspec. 107 (13) 1 (3) 297 (10) 0 (0) 61 (7) 65 (7) 1 (14) 39 (8) 5 (3) 3 (7) 76 (11) 49 (5) 57 (19)
Grade II 19 (2) 1 (3) 85 (3) 2 (3) 24 (3) 24 (3) 0 (0) 6 (1) 4 (2) 2 (4) 8 (1) 39 (4) 6 (2)
Grade I 33 (4) 1 (3) 52 (2) 0 (0) 27 (3) 19 (2) 0 (0) 8 (2) 2 (1) 3 (7) 15 (2) 18 (2) 9 (3)
Grade III, unspec. 16 (2) 0 (0) 54 (2) 0 (0) 16 (2) 46 (5) 0 (0) 7 (2) 4 (2) 1 (2) 16 (2) 29 (3) 12 (4)
Marginal zone BCL,
NOS
46 (6) 2 (6) 200 (7) 11 (15) 51 (6) 64 (7) 0 (0) 16 (3) 0 (0) 3 (7) 34 (5) 42 (5) 15 (5)
Lymphoblastic
(diffuse)
lymphoma
10 (1) 1 (3) 4 (0) 1 (1) 11 (1) 2 (0) 0 (0) 1 (0) 0 (0) 1 (2) 2 (0) 1 (0) 0 (0)
NOS, not otherwise speciﬁed; BCL, small-cell B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; Unspec, unspeciﬁed.
a Cases and percentages were calculated using aggregated data from regional cancer registries.
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incidence of ENKTL is high in some Asian countries, Central America
and West Indies(MexicoandGuatemala), Peruand Brazil,whereas in
North America and Europe this cancer subtype is rarely observed
[44]. A high frequency of ENKTL has also been reported in Asians and
Asian Americans [34;35]. Laurini et al. [30] suggested that the Asian
ancestry of the population in the countries located along the west
coast of the Central and South American region corresponds to the
high frequency of ENKTL. Unfortunately, cancer registries in the
region do not systematically collect information about race/
ethnicity; we were therefore unable to evaluate this hypothesis
further.
NHL has been reported in 2–3% of persons with AIDS; however,
AIDS accounts for only a small fraction of all NHL cases [6]. In most
countries of Central and South America, the prevalence of human
immunodeﬁciency virus (HIV) among adults (15–49-year-olds) in
2013 was 0.6%, – except for Belize and Guyana (1.5% and 1.4%,
respectively) – which is lower than the global prevalence of HIV in
15–49-year-olds (0.8%) and in Africa (5.5%) [45]. In Brazil, a study of
the geographic distribution of Burkitt lymphoma cases showed
that of 14 HIV-positive cases, ten of whom were EBV-positive
(71%), suggesting that this prevalence is similar to that in Africa
(75%, six EBV-positive cases/eight HIV-associated Burkitt lympho-
ma cases) [43].
In countries where the prevalence of HCV seropositivity in the
general population is high (i.e. Italy), approximately 10% of the NHL
cases are attributable to HCV, whereas in countries where the
prevalence of HCV is very low (<1%) only 1% of the cases are
attributable to this infection [46]. In 2010, the estimated
prevalence of HCV in the adult population in Argentina, Brazil,
Mexico, Peru and Venezuela is relatively low (ranging from 1.4 to
2.5%, 1.5% for all ages) [47].
Approximately 85–90% of the low-grade and 40–75% of the
high-grade gastric-mucosa-associated lymphoid tissue (MALT)
lymphomas are associated with Helicobacter pylori [6,48]. The
NHL–CSA study [30] showed an overall frequency of marginal-
zone B-cell lymphoma MALT type of 6.9% (ranging between 4 and
10.4%), similar to the frequency in North America (6.2%). In
developing countries, most people acquire H. pylori infection
during early childhood, and infection is strongly related to age and
low socioeconomic status [49]. In our study, we could not estimate
the proportion of MALT lymphomas given the lack of speciﬁc data;
6% of all B-cell neoplasms were classiﬁed as marginal-zone B-cell
lymphoma NOS, and these lymphomas can be further classiﬁed as
either MALT or small-cell B-cell lymphoma.
In some parts of Japan, the Caribbean Basin, Africa (Central and
West), and South America, adult T-cell leukemia/lymphoma is
endemic, accounting for more than 50% of all NHL cases [6]. Human
T-cell lymphotropic virus (HTLV-I) infection is also endemic in
populations of African ancestry from the Caribbean islands as well as
insomeareasinBrazil,Colombia,Guyana,FrenchGuyana,Nicaragua,
Panama, and Suriname, where the prevalence of the infection is
between 1% and 5% [50]. Carneiro et al. [51] reported a similar
prevalence of HTLV-1 across all 13 countries in the South American
region (between <0.1% and 5%), and described the presence of HTLV-
1 infection among Amerindian populations in Argentina, central and
southern Bolivia, northern and southern Chile, southern Colombia,
Paraguay, and southeastern Peru. The CSA–NHL study revealed that
the overall frequency of adult T-cell leukemia/lymphoma was higher
in the ﬁve countries evaluated than in North America (1.1% versus 0%,
P < 0.05), with the highest frequency of this malignancy observed in
Peru (5.5) [30]. In our study, this subtype was not registered (ICD-
03: 9827), again probably due to the lack of sufﬁciently speciﬁc data
for lineage-based classiﬁcation.
Occupational exposures to pesticides and herbicides have been
associated with an increased risk of NHL in the developed world [52–
Table 6
Biological agents potentially related to non-Hodgkin lymphoma (NHL) in Central and South America [40].
Infectious agent Cancer site
Epstein–Barr virus (EBV) Burkitt lymphoma, ENKTL (nasal type), NHL (immunosuppression related)
Hepatitis C virus (HCV) NHL
HIV type 1 NHL
Human T-cell lymphotropic virus type 1 (HTLV-I) Adult T-cell lymphoma
Helicobacter pylori Low-grade B-cell MALT gastric lymphoma
ENKTL, extranodal NK/T-cell lymphoma; MALT, mucosa-associated lymphoid tissue.
M.C. Diumenjo et al. / Cancer Epidemiology 44S (2016) S168–S177 S17555].TheseresultsareofparticularrelevancefortheCentralandSouth
American region given that agriculture is a major economic activity
[56,57]. While most countries in the region do not systematically
report annul use of pesticides (insecticides, herbicides, fungicides
and others) to the Food and Agricultural Organization of the United
Nations [58], limited data suggest that pesticide use has steadily
increased since the 1990s until the mid-2000s. Globally, Mexico,
Brazil and Colombia ranked among the top three to six country users
of insecticides, herbicides, fungicides and bactericides between 1961
and 2010 [59]. Occupational exposures to organophosphorus
herbicide (glyphosate) and phenoxy herbicide have also been
associated with an increased risk of B-cell lymphoma, lymphocytic
lymphoma, and DLBCL [54]. In our study, B-cell lymphoma –
speciﬁcally DLBCL – was the most frequently diagnosed NHL subtype
in the region. Future epidemiological studies on occupational
exposure to these agents in Central and South America could help
elucidate their role in NHL risk.
Other risk factors – such as receipt of solid organ transplants
[60–62] and the use of some immunosuppressive drugs [40] – are
likely to be responsible for a very small proportion of NHL cases
given the low prevalence in the general population. Numerous
studies have linked autoimmune disorders [63,64], type-2 diabetes
[65], and blood transfusions [66] with an increased risk of
developing NHL. Several other factors – such as family history of
lymphoma, use of hair-dyes [67,68] and lifestyle factors (i.e.
smoking, alcohol consumption, obesity) – have also been related to
an increased risk of NHL, although not consistently so [6,69–74].
The extent to which these factors may have contributed to the
observed geographic variation in NHL rates in our study is
unknown. Future etiological studies are still needed to evaluate
these potential associations.
4.2. Strengths and weaknesses of study
This study has several strengths and limitations. We present the
most comprehensive and up-to-date analysis of the burden of NHL
in Central and South America. However, incidence data patterns
must be interpreted with caution because national incidence was
estimated using aggregated data from local registries, most of
which did not cover the entire country, except for the national
cancer registries of Costa Rica and Uruguay. Changes in NHL
classiﬁcation and differences in case ascertainment and registra-
tion could have impacted the observed rates. Cancer registries in
Central and South America may differ in completeness and data
quality which, among other factors, depend on the maturity of the
cancer registry, which could explain the low NHL incidence rates
observed in Bolivia, El Salvador, and Mexico. Approximately 34% of
NHL cases diagnosed in Central and South America were classiﬁed
as unspeciﬁed, which indicates poor diagnostic precision [75]. It is
possible that misclassiﬁcation of disease status by histological
subtype biased the reported distribution: not only because of the
large proportion of unspeciﬁed cases but also because of high
inter-observer variability [12;13]. This highlights the urgent need
to improve coverage and quality of cancer registrations in the
region in order to minimize missing or incomplete data.
Furthermore, the estimation of NHL mortality rates is alsoinﬂuenced by the quality of national death certiﬁcation data
which, in some Central and South American countries, may be
considered of medium or low quality [76]. Given the anticipated
increase in NHL rates in Central and South America, there is an
overwhelming need for high-quality data and increased coverage
to provide vital guidance for cancer control activities.
5. Conclusion
NHL incidence and mortality rates varied between Central and
South America countries between 2 and 8- and 6-fold, respectively.
Males had incidence and mortality rates up to twice as high as those
in females. Uruguay had the one of highest NHL mortality rates in the
world in both males and females. According to the histological
distribution, B-cell lymphoma  speciﬁcally DLBCL NOS  was the
most frequent diagnosis in the region. The geographic variations in
NHL incidence and mortality rates may reﬂect differences in case
ascertainment and registration, disease diagnosis and classiﬁcation,
making interpretation of NHL patterns and trends challenging. This
study underlined the need to improve the quality of NHL
registrations as 34% of the tumors were unspeciﬁed. Given the
anticipated increase in NHL rates in Central and South America, there
is an overwhelming need for high-quality data and increased
coverage to provide vital guidance for cancer control activities.
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